(Q37590851)

21 August 2017

1 reference

title

Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events (English)

1 reference

21 August 2017

0 references

1 reference

cytomegaloviral disease

1 reference

Beth C Marshall

1

1 reference

PubMed ID

19725597

21 August 2017

William C Koch

series ordinal

2

1 reference

21 August 2017

1 January 2009

1 reference

21 August 2017

1 reference

21 August 2017

11

1 reference

21 August 2017

5

1 reference

21 August 2017

309-321

1 reference

https://scigraph.springernature.com/pub.10.2165/11316080-000000000-00000

21 August 2017

0 references

cites work

Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group.

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11316080-000000000-00000

Human pharmacokinetics of the antiviral drug DHPG.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11316080-000000000-00000

Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11316080-000000000-00000

Infectious Diseases Society of America and Centers for Disease Control: Summary of a Workshop on Surveillance for Congenital Cytomegalovirus Disease

21 January 2018

1 reference

12 December 2020

Cytomegalovirus drug resistance and clinical implications

1 reference

12 December 2020

Ganciclovir. An update of its therapeutic use in cytomegalovirus infection

1 reference

12 December 2020

VALGANCICLOVIR FOR CONGENITAL CMV INFECTION: A PILOT STUDY ON PLASMA CONCENTRATION IN NEWBORNS AND INFANTS

1 reference

12 December 2020

Clinical uses of cidofovir

1 reference

12 December 2020

Antiviral drugs for cytomegalovirus diseases

1 reference

12 December 2020

Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections

1 reference

12 December 2020

Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir

1 reference

12 December 2020

Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Antiviral therapy of congenital cytomegalovirus infection

1 reference

12 December 2020

Pharmacokinetics of ganciclovir in pediatric renal transplant recipients

1 reference

12 December 2020

Antiviral therapy for cytomegalovirus infections in pediatric patients

1 reference

12 December 2020

Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group

1 reference

12 December 2020

Antiviral therapies in children: has their time arrived?

1 reference

12 December 2020

The effect of cidofovir on cytomegalovirus-induced hearing loss in a Guinea pig model

1 reference

12 December 2020

Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens

1 reference

12 December 2020

Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation

1 reference

12 December 2020

Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease.

1 reference

12 December 2020

Seroprevalence of cytomegalovirus infection in the United States, 1988-1994

1 reference

12 December 2020

Stability of valganciclovir in extemporaneously compounded liquid formulations

1 reference

12 December 2020

Resistance of human cytomegalovirus to antiviral drugs

1 reference

12 December 2020

Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir

1 reference

12 December 2020

Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

1 reference

12 December 2020

Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation

1 reference

12 December 2020

Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children

1 reference

12 December 2020

Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation

1 reference

12 December 2020

Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients

1 reference

12 December 2020

Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus— and cytomegalovirus-seropositive patients

1 reference

12 December 2020

Polymerase chain reaction-based "pre-emptive" therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study

1 reference

12 December 2020

Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients

1 reference

12 December 2020

Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation

1 reference

12 December 2020

Valganciclovir: an advance in cytomegalovirus therapeutics

1 reference

12 December 2020

Advances in the antiviral therapy of herpes virus infection in children.

1 reference

12 December 2020

Cyclic cidofovir (cHPMPC) prevents congenital cytomegalovirus infection in a guinea pig model

1 reference

12 December 2020

The pharmacokinetics of antiviral therapy in paediatric patients.

1 reference

12 December 2020

Maternal factors affecting the integrity of the late gestation placental barrier to murine enterovirus infection

1 reference

12 December 2020

Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant

1 reference

12 December 2020

Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease

1 reference

12 December 2020

Foscarnet therapy for congenital cytomegalovirus liver fibrosis following prenatal ascites

1 reference

12 December 2020

Valganciclovir for treatment of congenital cytomegalovirus infection

1 reference

12 December 2020

Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections

1 reference

12 December 2020

Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?

1 reference

12 December 2020

High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes

1 reference

12 December 2020

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

1 reference

12 December 2020

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

1 reference

12 December 2020

The acyclic nucleoside phosphonates from inception to clinical use: historical perspective

1 reference

12 December 2020

Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl.

1 reference

12 December 2020

Quantification of cidofovir in human serum by LC-MS/MS for children

1 reference

12 December 2020

Successful treatment with oral valganciclovir in immunocompetent infant with gastrointestinal manifestations of cytomegalovirus infection.

1 reference

12 December 2020

Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids.

1 reference

12 December 2020

Isolation of Intranuclear Inclusion Producing Agents from Infants with Illnesses Resembling Cytomegalic Inclusion Disease

1 reference

12 December 2020

Pharmacokinetics of valganciclovir and ganciclovir in renal impairment

1 reference

12 December 2020

10.2165/11316080-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

19725597

Dimensions Publication ID

21 August 2017

0 references

1 reference

PubMed ID

19725597